Wednesday 01 May, 2024 01:58 PM
Site map | Locate Us | Login
   Exide Inds gains as Q4 PAT jumps 36% YoY to Rs 284 cr    IOCL slips after Q4 PAT slumps 52% YoY to Rs 4,838 cr    Newgen Software Tech hits lifetime high as Q4 PAT climbs 54% QoQ    P&G Hygiene slips as Q3 PAT slides 6% YoY to Rs 154 cr    Patel Engineering Ltd leads losers in 'A' group    REC spurts on recording good Q4 performance    Shiva Mills Ltd leads losers in 'B' group    Sprayking soars after order win    Volumes soar at SBFC Finance Ltd counter    Metal shares slide    Information Technology stocks slide    KFin Tech hits record high after Q4 PAT jumps 30% YoY    Spandana Sphoorty records 22% YoY growth in Q4 PAT; AUM at Rs 11,973 crore    Granules India gains after receiving US FDA nod for gout medicine    APL Apollo Tubes Ltd rises for third straight session 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Marksans Pharma declines after US FDA issues Form 483 with 5 observations to Goan plant
18-Apr-24   11:52 Hrs IST

The US drug regulator had conducted a routine current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility of the company located in Vema, Goa, India, from 9 April 2024 to 17 April 2024.

On conclusion of the inspection, the company has received 5 inspectional observations in Form 483. There is no data integrity observation.

The company will work closely with the USFDA and is committed to address these observations comprehensively within the stipulated time,? Marksans Pharma said in a statement.

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

The company?s consolidated net profit jumped 33.69% to Rs 83.29 crore in Q3 FY24 as compared with Rs 62.30 crore in Q3 FY23. Revenue from operations increased 22.15% YoY to Rs 586.12 crore in Q3 FY24.

Powered by Capital Market - Live News
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Investor Charter | Annual Return | Span Margin | Disclaimer | Feed Back | Privacy Policy | Policies & Procedures |Rights & Obligations-English| Rights & Obligations-தமிழ் | Anti Money Laundering Policy | E-Voting | CSR Hit Count : 32287981
Useful Links : NSE | BSE | MCX | NSDL | CDSL | SEBI | RBI | ATTENTION INVESTOR| SMART ODR
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd